Abstract
Purpose
In recent years, therapeutic strategies based on tumour biology have increased significantly. We aimed to provide an overview of the recent changes in patient characteristics, treatment procedures and survival factors for two groups of patients: women younger than 35 years and women between 50 and 69 years.
Methods
We used data from the population-based Cancer Registry Magdeburg. Subjects included women with non-metastatic breast cancer treated between 2000 and 2015. We compared between two observation periods: 2000–2007 and 2008–2015.
Results
There was an increase in patient survival from the first to the second observation period. Tumour characteristics and treatment modalities changed, especially in the group of older patients. The proportion of prognostically more favourable tumour subtypes, such as Luminal A, increased significantly. Between 2008 and 2015, there were more hormone receptor-positive, lymph-node-negative, human epidermal growth factor receptor-2 (HER2)-negative and well-differentiated tumours. Surgical methods were associated with significantly reduced radicality, while the rate of neoadjuvant therapy increased in both groups. There was a decrease in cyclophosphamide, methotrexate and 5-fluoruracil (CMF) and anthracycline therapies, but taxane-containing chemotherapy increased. While tamoxifen was used more frequently in younger patients in the later observation period, its use was reduced in older patients, superseded by aromatase inhibitors. Furthermore, the use of immune therapy increased.
Conclusion
In both age groups, but primarily in older patients, there were significant changes in tumour biology and treatment options between the two observation periods. These changes have led to a continuous improvement in patient outcomes.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
The datasets analysed during the current study are available from the corresponding author upon reasonable request.
References
Arbeitsgemeinschaft Gynäkologische Onkologie (2020) Leitlinien/Empfehlungen - Gynäkologische Onkologie Kommission Mamma. https://www.ago-online.de/leitlinien-empfehlungen/leitlinien-empfehlungen/kommission-mamma. Accessed 28 Aug 2020
Bachleitner-Hofmann T, Taucher S (2007) Operative Überlegungen beim Famillären Mammakarzinom. Mammakarzinom. Springer, Vienna, pp 93–106
Baumann R, Dunst J (2016) Prognose von sehr jungen Patientinnen mit Mammakarzinom. Strahlenther Onkol 192:737–738. https://doi.org/10.1007/s00066-016-1033-5
Baumann R, Dunst J (2017) Brusterhaltende Therapie mit adjuvanter Radiotherapie des Mammakarzinoms besser als die Mastektomie? Aktuelle 10-Jahres-Daten aus den Niederlanden. Strahlenther Onkol 193:344–346. https://doi.org/10.1007/s00066-017-1111-3
Bedard PL, Di Leo A, Piccart-Gebhart MJ (2010) Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer. Nat Rev Clin Oncol 7:22–36. https://doi.org/10.1038/nrclinonc.2009.186
Biesheuvel C, Weigel S, Heindel W (2011) Mammography screening: evidence, history and current practice in germany and other european countries. Breast Care Basel Switz 6:104–109. https://doi.org/10.1159/000327493
Statistisches Bundesamt (Destatis) (2020) Todesursachenstatistik Deutschland
Statistisches Bundesamt (2020) Die 10 häufigsten Todesfälle durch Krebs. In: Stat. Bundesamt. https://www.destatis.de/DE/Themen/Gesellschaft-Umwelt/Gesundheit/Todesursachen/Tabellen/sterbefaelle-krebs-insgesamt.html. Accessed 8 Jul 2020
Carter CL, Allen C, Henson DE (1989) Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 63:181–187. https://doi.org/10.1002/1097-0142(19890101)63:1%3c181::aid-cncr2820630129%3e3.0.co;2-h
De Laurentiis M, Cancello G, D’Agostino D et al (2008) Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol 26:44–53. https://doi.org/10.1200/JCO.2007.11.3787
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Peto R, Davies C et al (2012) Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet Lond Engl 379:432–444. https://doi.org/10.1016/S0140-6736(11)61625-5
Early Breast Cancer Trialists’ Collaborative Group (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351:1451–1467. https://doi.org/10.1016/S0140-6736(97)11423-4
Early Breast Cancer Trialists’ Group (2015) Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 386:1341–1352. https://doi.org/10.1016/S0140-6736(15)61074-1
Fehm T, Stickeler E (2021) Neoadjuvante, adjuvante und postneoadjuvante Therapiestrategien beim frühen Mammakarzinom zur Eskalation und Deeskalation: TNBC, HER2+ sowie ER+/PR+/HER2−. Onkol. https://doi.org/10.1007/s00761-021-01025-3
Ferguson T, Wilcken N, Vagg R et al (2007) Taxanes for adjuvant treatment of early breast cancer. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD004421.pub2
Fisher B, Anderson S, Bryant J et al (2002) Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 347:1233–1241. https://doi.org/10.1056/NEJMoa022152
Garreau JR, Delamelena T, Walts D et al (2006) Side effects of aromatase inhibitors versus tamoxifen: the patients’ perspective. Am J Surg 192:496–498. https://doi.org/10.1016/j.amjsurg.2006.06.018
Gebauer G, Fehm T, Lang N, Jäger W (2002) Tumor size, axillary lymph node status and steroid receptor expression in breast cancer: prognostic relevance 5 years after surgery. Breast Cancer Res Treat 75:167–173. https://doi.org/10.1023/a:1019601928290
Goldhirsch A, Winer EP, Coates AS et al (2013) Personalizing the treatment of women with early breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2013. Ann Oncol off J Eur Soc Med Oncol 24:2206–2223. https://doi.org/10.1093/annonc/mdt303
Grumpelt A-M, Ignatov A, Tchaikovski SN et al (2016) Tumor characteristics and therapy of elderly patients with breast cancer. J Cancer Res Clin Oncol 142:1109–1116. https://doi.org/10.1007/s00432-015-2111-2
Heublein S, Burgert S, Marme F, et al (2018) Der Einfluss des Patientinnenalters auf Therapie und Prognose des Mammakarzinoms. Berlin, p s-0038–1671223
Huiart L, Bouhnik A-D, Rey D et al (2012) Early discontinuation of tamoxifen intake in younger women with breast cancer: Is it time to rethink the way it is prescribed? Eur J Cancer 48:1939–1946. https://doi.org/10.1016/j.ejca.2012.03.004
Janni W, Rack B, Sommer H, Friese K (2006) Kongressbericht. Stellenwert neuer Behandlungsmöglichkeiten mit “Biologicals” beim Mammakarzinom und Neuigkeiten vom ASCO 2006. Geburtshilfe Frauenheilkd 66:692–695. https://doi.org/10.1055/s-2006-924498
Katalinic A (2009) Sinkende Mortalität bei steigender Inzidenz beim Mammakarzinom. Geburtshilfe Frauenheilkd 69:237–239. https://doi.org/10.1055/s-0029-1185421
Katzorke N, Rack B, Häberle L et al (2013) Prognostische Relevanz des HER2/neu Status für das Überleben von Brustkrebspatientinnen. Senol - Z Für Mammadiagnostik -Ther. https://doi.org/10.1055/s-0033-1347601
Killelea BK, Yang VQ, Mougalian S et al (2015) Neoadjuvant chemotherapy for breast cancer increases the rate of breast conservation: results from the national cancer database. J Am Coll Surg 220:1063–1069. https://doi.org/10.1016/j.jamcollsurg.2015.02.011
Klinische Krebsregister Sachsen-Anhalt gGmbH (2018) Jahresbericht Klinisches Krebsregister Sachsen-Anhalt. In: Jahresber. Klin. Krebsregister Sachs.-Anhalt. https://www.kkr-lsa.de/fileadmin/user_upload/krebsregister/pagecontent/veroeffentlichungen/2019/KKRLSA_Jahresbericht2017_final.pdf. Accessed 16 Jul 2020
Kolberg HC, Friedrich M, Diedrich K (2004) Sentinel-Lymphknoten-Biopsie in der Therapie des Mammakarzinoms: Historischer Überblick und aktueller Stand. Gynäkol. https://doi.org/10.1007/s00129-004-1560-5
Kreienberg R (ed) (2010) Mammakarzinom, interdisziplinär: mit 103 Tabellen, 4th edn. Springer Medizin, Berlin
Kroman N, Holtveg H, Wohlfahrt J et al (2004) Effect of breast-conserving therapy versus radical mastectomy on prognosis for young women with breast carcinoma. Cancer 100:688–693. https://doi.org/10.1002/cncr.20022
T. Kühn, A. Bembenek (2003) Sentinel-Node-Biopsie beim Mammakarzinom Interdisziplinär abgestimmter Konsensus der Deutschen Gesellschaft für Senologie für eine qualitätsgesicherte Anwendung in der klinischen Routine
KVSA (2006) Regelungen zur Einführung eines flächendeckenden Mammographie-Screenings in Sachsen-Anhalt
Leclère B, Molinié F, Trétarre B et al (2013) Trends in incidence of breast cancer among women under 40 in seven European countries: a GRELL cooperative study. Cancer Epidemiol 37:544–549. https://doi.org/10.1016/j.canep.2013.05.001
Li CI, Daling JR, Malone KE (2003) Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998. J Clin Oncol 21:28–34. https://doi.org/10.1200/JCO.2003.03.088
Nagel G, Röhrig B (2002) Bevölkerungsbezogene Studie über die Anwendung adjuvanter Strahlentherapie bei Patientinnen mit Mammakarzinom. Nr 11:589–596. https://doi.org/10.1007/s00066-002-0985-9
Pronzato P, Mustacchi G, De Matteis A et al (2011) Biological characteristics and medical treatment of breast cancer in young women—a featured population: results from the NORA study. Int J Breast Cancer 2011:1–6. https://doi.org/10.4061/2011/534256
Robert Koch Institut (2016) Bundesgesundheitsministerium - Bericht zum Krebsgeschehen in Deutschland 2016. In: Bundesgesundheitsministerium - Ber. Zum Krebsgesch. Dtschl. 2016. https://www.bundesgesundheitsministerium.de/fileadmin/Dateien/3_Downloads/K/Krebs/Krebsgeschehen_RKI.pdf. Accessed 8 Jul 2020
Robert Koch Institut (2017) Gesundheitsberichterstattung des Bundes, Heft 25. https://www.rki.de/EN/Content/Health_Monitoring/Health_Reporting/GBEDownloadsT/brustkrebs.pdf?__blob=publicationFile. Accessed 17 Jul 2020
Robert Koch Institut (2020) Zentrum für Krebsregisterdaten. In: Zent. Für Krebsregisterdaten. https://www.krebsdaten.de/Krebs/DE/Content/Krebsarten/Brustkrebs/brustkrebs_node.html. Accessed 8 Jul 2020
Roterberg K, Blumenröther M (2006) Sentinel-Node-Biopsie in der klinischen routine: 4-jährige Erfahrung bei 768 Mammakarzinom-Patientinnen. Senol - Z Für Mammadiagnostik -Ther. https://doi.org/10.1055/s-2006-953650
Schrodi S, Braisch U, Geiss K, Schenkirsch G (2011) Bevölkerungsbezogene Auswirkungen des Mammografie-Screenings auf die Therapien des Mammakarzinoms. Eine Analyse bayerischer Krebsregisterdaten. Senol - Z Für Mammadiagnostik -Ther. https://doi.org/10.1055/s-0031-1278181
Smith RA (2000) Breast cancer screening among women younger than age 50: a current assessment of the issues. CA Cancer J Clin 50:312–336. https://doi.org/10.3322/canjclin.50.5.312
The Breast International Group (2005) A Comparison of Letrozole and Tamoxifen in Postmenopausal Women with Early Breast Cancer. N Engl J Med 353:2747–2757. https://doi.org/10.1056/NEJMoa052258
Untch M, Stickeler E (2018) Neoadjuvante Therapie bei Patientinnen mit Mammakarzinom. Gynäkol 51:531–539. https://doi.org/10.1007/s00129-018-4273-x
Van Ewijk RJG, Schwentner L, Wöckel A et al (2013) Trends in patient characteristics, treatment and survival in breast cancer in a non-selected retrospective clinical cohort study of 2,600 patients. Arch Gynecol Obstet 287:103–110. https://doi.org/10.1007/s00404-012-2544-7
Varga D, Wöckel A, Debatin I, Kreienberg R (2009) Brustkrebs: die junge Patientin. Gynäkol 42:671–674. https://doi.org/10.1007/s00129-009-2358-2
Winzer K-J, Buchholz A, Guski H et al (2013) Treatment of primary breast cancer at the surgical unit of the Charité 1984–1998. Oncol Res Treat 36:5–5. https://doi.org/10.1159/000356805
Würstlein, R (2014) Die junge Mammakarzinom-Patientin. http://www.klinikum.uni-muenchen.de/Brustzentrum/download/inhalt/publikationen/2014/DIAG_Wuerstlein_04.pdf. Accessed 17 Jul 2020
Yin W, Jiang Y, Shen Z et al (2011) Trastuzumab in the adjuvant treatment of HER2-positive early breast cancer patients: a meta-analysis of published randomized controlled trials. PLoS One. https://doi.org/10.1371/journal.pone.0021030
Zabicki K, Colbert JA, Dominguez FJ et al (2006) Breast cancer diagnosis in women < or = 40 versus 50 to 60 years: increasing size and stage disparity compared with older women over time. Ann Surg Oncol 13:1072–1077. https://doi.org/10.1245/ASO.2006.03.055
Acknowledgements
Our thanks go to Elke Burger and all employees of the Cancer Registry Magdeburg for collecting, managing, and storing the presented data. Furthermore, we thank all the medical staff who have reported the data to the cancer registry and have enabled scientific progress.
Funding
The authors declare that no funds, grants, or other supports were received during the preparation of this manuscript.
Author information
Authors and Affiliations
Contributions
A. and E. wrote the manuscript. C. provided data. All authors reviewed the manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Conflict of interest
All authors declare that they have no conflict of interest.
Ethical approval
This article does not contain any studies with animals performed by any of the authors. In accordance with the statement of the Research and Ethical Committee of the Otto-von-Guericke University, Magdeburg, Germany, additional individual consent for this analysis was not needed.
Informed consent
Written informed consent was obtained from all patients before treatment. Additional individual consent for this analysis was not needed.
Consent to participate
Informed consent was obtained from all individual participants included in the study.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Schreiber, J., Ignatov, A., Burger, E. et al. Breast cancer therapy in women under 35 years and between 50 and 69 years: influence of the observation period. J Cancer Res Clin Oncol 149, 5665–5676 (2023). https://doi.org/10.1007/s00432-022-04520-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-022-04520-1